Redeye argues that the EBIT miss does not bring any concern to the longer-term profitability (or cash flow) outlook for BONESUPPORT and that during 2024e, this will become more apparent. The dramatic negative share price reaction provides attractive entry points in this aggressive sales growth case, which has yet only begun scratching the surface of its market potential. We reiterate our SEK256 base case and see several key catalysts to close the gap during the year.